Société Tunisienne des Maladies Respiratoires et d'Allergologie STMRA - M-A: Tocilizumab in COVID-19 – “For hospitalized COVID-19 patients, there is some evidence that tocilizumab use may be associated with a short-term mortality benefit, but further high-quality data are required”.

M-A: Tocilizumab in COVID-19 – “For hospitalized COVID-19 patients, there is some evidence that tocilizumab use may be associated with a short-term mortality benefit, but further high-quality data are required”.

Zouhair Souissi

24 mai 2021

Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials – Intensive Care Medicine Commentary on Twitter Tocilizumab as IL-6 antagonist in hospitalized #COVID19 pts, SR/MA/TSA:➡️10 RCTs/6493 pts (52.2% ➡️ tocilizumab)➡️some evidence suggests tocilizumab may be associated with short-term mortality benefit➡️tocilizumab may prevent disease progression to MVhttps://t.co/sWR4Y351sl pic.twitter.com/JPD31Nb5rn — Intens Care […]

The post M-A: Tocilizumab in COVID-19 – “For hospitalized COVID-19 patients, there is some evidence that tocilizumab use may be associated with a short-term mortality benefit, but further high-quality data are required”. appeared first on Links Medicus.

Lu 586 fois